Immunogenicity of the HO-1 Peptide eluted from Renal Cell Carcinoma for CD8 T cells

Inaugural-Dissertation
Zur Erlangung des Doktorgrades
der Medizin
der Medizinischen Fakultät
der Eberhard-Karls-Universität
zu Tübingen

vorgelegt von
Veneta Hristova Grigorova
aus
Sofia/Bulgarien

2010
ACKNOWLEDGEMENTS

I would like to thank the following people for their help and support during my stay in Tubingen:

Dekan: Professor Dr. I. B. Autenrieth
1. Berichterstatter: Professor Dr. G. Pawelec
2. Berichterstatter: Professor Dr. S. Stevanović
Professor Dr. Graham Pawelec at the University of Tubingen for accepting me into his group, for his scientific input and assistance, for being an excellent supervisor and for his useful advice and comments.

Dr. Ludmila Mueller for being a good teacher and friend. Her advice during the practical work was always useful.

Ashley Knights and Evelyna Derhovanessian both for their help in my practical work and being good friends and teachers.

The people of the TATI group, past and present, especially Karin Hähnel and Arnika Rehbein as well as other groups (especially Jon Tolson) who were always friendly and wiling to help.

Last but not least, I would like to thank all the members of my family, especially my mother, for their financially and emotionally support, as well as my close friends for their constant support.
1. Introduction
1.1 Immune response to cancer
1.1.1 Innate Immunity
1.1.2 Adaptive Immunity
1.1.2.1 Antigen presentation_processing
1.1.2.2 MHC Class I-restricted immunity
1.1.2.3 Cross-presentation
1.1.3 Tumour antigens
1.1.4 Techniques for the identification of tumour antigens
1.1.5 Reverse immunology
1.1.6 Manipulating the immune response
1.2 Renal cell cancer

2. Material and Methods
2.1 Isolation of PBMC
2.2 HLA typing
2.3 Synthetic peptides
2.4 Cultivation of cell lines
2.4.1 Quantification of cell number and viability
2.4.2 Cryopreservation of cells
2.5 Dendritic cell generation
2.6 Generation of T cell lines
2.6.1 Cytokine-modified bulk-culture protocol
2.6.2 Dendritic cell sensitisation
2.7 Inactivation of cells used as antigen presenting cells
2.8 Enzyme-linked immunosorbent assay (ELISA)
2.9 IFN-γ ELISpot assay
2.10 Effector-cell degranulation assay

3. Results
3.1 Generation of specific T-cell lines from PBMC of healthy donor, using synthetic HO-I peptide
3.2 Screening the established T-cell lines for HO-1 specific
cytokine release by ELISA 29

3.3 Measurement of antigen-specific IFN-γ production by T lymphocytes at the single cell level by ELISpot assay 30

3.4 Evaluation of antigen-specific cytolytic activity of the generated peptide-specific T-cell line by CD107a mobilisation assay 36

4. Discussion 40

5. Abstract 52

6. Zusammenfassung 54

7. List of abbreviations 56

8. Reference List 58

9. Reference List – Alphabetic order 68

10. CV (Lebenslauf) 79